Changes in Soluble Transferrin Receptor and Hemoglobin Concentrations in Malawian Mothers Are Associated with Those Values in their Exclusively Breastfed, HIV-Exposed Infants1–3

Elizabeth M. Widen,4* Margaret E. Bentley,5,6 Dumbani Kayira,9 Charles S. Chasela,10 Eric J. Daza,7 Zebrone K. Kacheche,6 Gerald Tegha,9 Denise J. Jamieson,11 Athena P. Kourtis,11 Charles M. van der Horst,8 Lindsay H. Allen,12 Setareh Shahab-Ferdows,12 and Linda S. Adair,5,6 for the BAN Study Team

Abstract

Infant iron status at birth is influenced by maternal iron status during pregnancy; however, there are limited data on the extent to which maternal iron status is associated with infant iron status during exclusive breastfeeding. We evaluated how maternal and infant hemoglobin and iron status [soluble transferrin receptors (TfR) and ferritin] were related during exclusive breastfeeding in HIV-infected women and their infants. The Breastfeeding, Antiretrovirals, and Nutrition Study was a randomized controlled trial in Lilongwe, Malawi, in which HIV-infected women were assigned with a 2 × 3 factorial design to a lipid-based nutrient supplement (LNS), or no LNS, and maternal, infant, or no antiretroviral drug, and followed for 24 wk. Longitudinal models were used to relate postpartum maternal hemoglobin (n = 1926) to concurrently measured infant hemoglobin, adjusting for initial infant hemoglobin values. In a subsample, change in infant iron status (hemoglobin, log ferritin, log TfR) between 2 (n = 382) or 6 wk (n = 167) and 24 wk (n = 519) was regressed on corresponding change in the maternal indicator, adjusting for 2 or 6 wk values. A 1 g/L higher maternal hemoglobin at 12, 18, and 24 wk was associated with a 0.06 g/L (P = 0.01), 0.10 g/L (P < 0.001), and 0.06 g/L (P = 0.01), respectively, higher infant hemoglobin. In the subsample, a reduction in maternal log TfR and an increase in hemoglobin from initial measurement to 24 wk were associated with the same pattern in infant values (log TfR; β = −0.18 mg/L, P < 0.001; hemoglobin β = 0.13 g/L, P = 0.01). Given the observed influence of maternal and initial infant values, optimizing maternal iron status in pregnancy and postpartum is important to protect infant iron status. This trial was registered at clinicaltrials.gov as NCT00164736. J. Nutr. 144: 367–374, 2014.

Introduction

Iron deficiency is believed to be the most common nutrient deficiency in low-income countries (1) and is associated with impaired neurodevelopment and immune function (2–4). Given the iron endowment at birth, the predominant opinion has been that infant iron stores are sufficient for 6 mo during exclusive breastfeeding (5,6). However, infants in resource-poor settings are prone to early depletion of iron stores, especially if maternal iron status was poor before or during pregnancy (7), they had shorter gestational age (7) or low birth weight (8,9), they were male (8), or they had rapid growth from 2 to 6 mo of age (10,11).

Whether maternal iron status is associated with infant iron status during breastfeeding, independently of infant iron stores at birth, is unclear. Understanding this relation is especially

1 The Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study was supported by grants from the Prevention Research Centers Special Interest Project of the CDC (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01); the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research (P30-AI50410), and the National Institutes of Health Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 TW00119-06 and R24 TW000798; the American Recovery and Reinvestment Act). The antiretrovirals used in the BAN Study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children’s Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson and Johnson, and the U.S. Agency for International Development. The Malawi Mothers and Infants project was supported by the Bill and Melinda Gates Foundation (Grant OPP53107) and the Carolina Population Center (R24 HD050924). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.


3 Supplemental Tables 1–3 are available from the "Online Supporting Material" link in the online posting of the article and from the same link in the online table of contents at http://jn.nutrition.org.
important in the context of HIV. HIV-infected women are at high risk of anemia during pregnancy and depleted iron stores postpartum (12,13). In resource-poor settings, 6 mo of exclusive breastfeeding by HIV-infected women coupled with antiretroviral drug (ARV) prophylaxis to the mother or infant is recommended to promote child survival and prevent mother-to-child transmission of HIV if replacement feedings are not acceptable, feasible, affordable, sustainable, and safe (14). Together, impaired maternal iron status, ARV prophylaxis (15), and exclusive breastfeeding may result in early depletion of infant iron stores.

Our objective was to examine the relationship between maternal and infant hemoglobin and iron status [ferritin and soluble transferrin receptors (TfR)] in participants of the Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study and in a subsample of BAN Study participants with additional biomarker assays.

Methods

Study population. Data are from the BAN Study, whose design (16) and primary intervention findings (17–20) have been reported elsewhere. The BAN Study was a randomized controlled trial conducted in Lilongwe, Malawi, from April 2004 to February 2010. Briefly, HIV-1-positive pregnant women (n = 3572) were recruited from 4 antenatal clinics and screened for initial eligibility criteria including: cluster of differentiation 4 count ≥ 250 cells/mm³, hemoglobin ≥ 70 g/L, and gestational age < 30 wk. As part of routine antenatal care, mothers received daily iron-folic acid supplementation containing 200 mg ferrous sulfate (40 mg elemental iron) and 0.25 mg folic acid. At delivery, eligible dyads (n = 2791) received peripartum single dose nevirapine and twicedaily zidovudine and lamivudine for 7 d. Within 36 h of delivery, dyads had to meet secondary eligibility criteria for random assignment (n = 2382). Of these dyads, 13 declined further participation (17).

Mother-infant dyads (n = 2369) were randomly assigned using a permuted-block method to 1 of 6 28-wk treatment arms according to a 2-arm nutritional and 3-arm antiretroviral factorial design. Half of the mothers received a daily lipid-based nutrient supplement [LNS (Nutriset)], which included 15 mg of elemental iron (Supplemental Table 1) (18). There was further randomization to maternal ARVs (a 3-drug, highly-active regimen), infant ARV (daily oral Nevirapine), or standard of care (17). On March 26, 2008, the data safety monitoring board halted enrollment in the no-ARV arms because there was evidence that HIV transmission through breast milk was higher in these groups (21).

Mothers enrolled in these arms who were <21 wk postpartum (n = 35) influenced the longitudinal model estimates. Power to detect a 0.25 difference in mean infant ferritin at an α of 0.05. Initial assays were conducted with 2-wk plasma in infants with sufficient plasma at that time; otherwise, initial assays were conducted with 6-wk plasma. Subsequent assays used 24-wk plasma. TfR and markers of inflammation [C-reactive protein (CRP) and α1-acid glycoprotein (AGP)] concentrations were measured using a Cobas Integra 400 (Roche Diagnostics). Ferritin was measured with the IRMA Ferritin Coat-a-Count radioimmunoassay (Siemens Health Care Diagnostics Inc.).

Statistical analysis. This paper focuses on 2 groups of dyads: those with longitudinal hemoglobin data and the subsample selected for TfR, ferritin, CRP, and AGP analyses. Infants weaned before 24 wk (n = 277) were excluded from longitudinal analyses following exclusive breastfeeding cessation, defined as receiving anything to eat or drink other than breast milk.

Dyads in the longitudinal analysis (n = 1926) had measurements of infant birth hemoglobin, birth weight, and concurrent maternal and infant hemoglobin at subsequent visits. Characteristics of this sample were compared with those of randomly assigned mothers excluded from the analysis because of insufficient data (n = 443) using t tests for continuous normally distributed variables and nonparametric tests for skewed continuous variables. These tests were also used to compare 1) subsample dyads (n = 519) with excluded dyads (n = 1850), and 2) longitudinal analysis subsample dyads (n = 498) with other longitudinal analysis dyads (n = 1428). Twenty-one subsample dyads were not included in the longitudinal analysis due to missing birth hemoglobin data.

In the longitudinal sample, linear regression was used to evaluate the association between maternal anemia during pregnancy [hemoglobin < 110 g/L (3)] and infant birth hemoglobin, adjusting for birth weight. Longitudinal random-effects models were used to evaluate the association between maternal hemoglobin and concurrently measured infant hemoglobin from 2 to 24 wk, adjusting for infant birth hemoglobin, sex, birth weight, ARV arms, and rate of weight gain since preceding visit. Study visit was used to model time. Because the iron in a maternal LNS is metabolized by the mother and then “theoretically” reflected in her iron status values, and does not affect the iron concentration in breast milk, it therefore does not exert an independent effect on infant iron status.

Thus, maternal LNS is not a confounder of this association and was not included in the models (23). Interactions of visits with rate of weight gain, infant birth hemoglobin, and ARV arms were evaluated using Wald tests for joint significance. No significant interactions were observed for the maternal ARV arm and visits [Wald χ²(4) = 2.01, P = 0.73], thus the interaction terms were not retained. Because some control dyads switched treatment arms, a sensitivity analysis was conducted to evaluate whether exclusion of these dyads after treatment changes (n = 35) influenced the longitudinal model estimates.
Infection and inflammation reduce hemoglobin and increase ferritin concentrations (26). Although TIR is thought to be less sensitive to inflammation and infection than ferritin (26), associations were observed between TIR and CRP and/or AGP. Therefore, TIR, hemoglobin, and ferritin in the subsample were adjusted for infection and inflammation using methods proposed by Thurnham and colleagues (27,28). Briefly, cut points defined elevated CRP (>5 mg/L) and AGP (>1 g/L) and stage of inflammation [healthy (normal CRP and AGP), incubation (elevated CRP), early convalescence (CRP and AGP elevated), and late convalescence (elevated AGP)] (28). Correction factors for each inflammation group were determined by dividing the median value of the healthy group by the median value of the other groups, and stage of inflammation [healthy (normal CRP and AGP), incubation (elevated CRP), early convalescence (CRP and AGP elevated), and late convalescence (elevated AGP)] (28). Correction factors for each inflammation group were determined by dividing the median value of the healthy group by the median value of the other groups, and stage of inflammation [healthy (normal CRP and AGP), incubation (elevated CRP), early convalescence (CRP and AGP elevated), and late convalescence (elevated AGP)] (28). Correction factors for each inflammation group were determined by dividing the median value of the healthy group by the median value of the other groups, and stage of inflammation [healthy (normal CRP and AGP), incubation (elevated CRP), early convalescence (CRP and AGP elevated), and late convalescence (elevated AGP)] (28).

In the subsample, linear regression was used to evaluate the association between change in inflammation-adjusted maternal iron status (hemoglobin, ferritin, and TIR) and change in inflammation-adjusted infant iron status (ferritin < 15 μg/L) at 2 or 6 wk were associated with increased odds of depleted infant iron stores (ferritin < 30 μg/L) at 2 or 6 wk and 24 wk (<12 μg/L), adjusting for birth weight, ARV arm, timing of initial measurement, sex, and for 24-wk models, initial infant value.

STATA 12.0 (StataCorp) was used for all statistical analyses. An α of 0.10 was used for all statistical tests of interaction (29); an α of 0.05 was used for all other statistical tests.

Results

Compared to those excluded because of incomplete data, HIV infection, or multiple birth, mothers (n = 1926) in the longitudinal analysis were older, had a lower prevalence of low cluster of differentiation 4, had higher pregnancy hemoglobin and less anemia during pregnancy, and fewer were primiparous (Supplemental Table 2). Infants in the longitudinal analysis had higher birth weight and length, and were more likely to be in the ARV arm (Supplemental Table 2). Compared to randomly assigned mothers, subsample mothers were older, had lower BMI at delivery, and were less likely to be married (Supplemental Table 2). A smaller proportion of subsample infants had low birth weight, and a larger proportion of infants were in the ARV arm (Supplemental Table 2). Of the 1926 dyads in the longitudinal

\[\text{FIGURE 1} \quad \text{Mean maternal Hb from birth to 24 wk (A) in the mLNS (n = 624), mLNS-mARV (n = 341), mARV (n = 338), and control (n = 623) arms of the longitudinal sample of BAN Study mother–infant dyads with at least 1 concurrent mother and infant Hb measurement. Mean infant Hb from birth to 24 wk (B) in the mLNS (n = 255), mLNS-mARV (n = 341), mARV (n = 338), iARV (n = 356), mLNS-iARV (n = 369), and control (n = 267) arms of the longitudinal sample with at least 1 concurrent mother and infant Hb measurement. BAN, Breastfeeding, Antiretrovirals, and Nutrition; C, control; Hb, hemoglobin; iARV, infant antiretroviral drug; LNS, lipid-based nutrient supplement; mLNS, maternal lipid-based nutrient supplement and maternal antiretroviral drug.} \]
analysis, 498 were in the subsample. Compared to mothers only in the longitudinal analysis (n = 1498), subsample mothers (n = 498) were older, had lower BMI at delivery, and were less likely to be in the ARV arm. In addition, a smaller proportion of infants had low birth weight and a larger proportion received the ARV intervention (Supplemental Table 2).

In general, mothers were young, multiparous, married, and had a low prevalence of under- or overweight at delivery, but more than half had anemia [hemoglobin < 110 g/L (3)] during pregnancy (Table 1). From delivery to 24 wk, maternal hemoglobin increased in the longitudinal sample (Figure 1) and prevalence of anemia decreased from 50% to 31%. In the subsample where we were able to adjust for inflammation, inflammation-adjusted maternal hemoglobin remained relatively stable from initial postpartum measurement to 24 wk, whereas maternal TfR declined (Table 2). Prevalence of depleted maternal iron stores (ferritin < 15 μg/L) declined from initial measurement to 24 wk, but in women measured at 6 wk, prevalence of depleted iron stores remained stable at 24 wk. Prevalence of tissue iron depletion (TfR > 8.3 mg/L) decreased from initial measurement to 24 wk.

Few infants had low birth weight, and mean infant hemoglobin concentrations at birth were within normal reference ranges based on a sample of infants from the United States (25). In the longitudinal sample, mean infant hemoglobin decreased from birth to 24 wk (Figure 1) and from 12–24 wk, and prevalence of low infant hemoglobin [<105 g/L (6)] increased from 43% to 50%. Infant ferritin declined markedly from baseline to 24 wk, consistent with normalization of values after erythrocyte breakdown, whereas TfR increased (Table 2). Few infants had abnormal initial indicators, but by 24 wk many infants began to show signs of poor iron status.

In the longitudinal sample, maternal anemia during pregnancy [hemoglobin < 110 g/L (3)] was associated with lower infant hemoglobin at birth [β = −2.33 g/L (95% CI: −4.13, −0.54), P = 0.01], adjusting for birth weight. In the longitudinal random-effects model (Supplemental Table 3), significant interactions were observed between study visits and maternal hemoglobin [Wald χ² (4) = 9.08, P = 0.06] (Figure 2). The strongest association was observed at 18 wk, where a 1 g/L increase in maternal hemoglobin was associated with 0.1 g/L higher infant hemoglobin. Female sex, higher birth weight, and infant birth hemoglobin were associated with higher infant hemoglobin at all visits. Faster infant growth, after adjusting for birth weight, was associated with lower hemoglobin at 6 wk [β = −3.64 g/L (95% CI: −5.19, −2.09), P < 0.001], but not at subsequent visits. Compared to controls, maternal ARVs were not associated with infant hemoglobin, whereas infant ARVs were associated with lower hemoglobin at 6 and 12 wk, but not at later visits. In the sensitivity analysis, exclusion of control participants who switched to an ARV treatment arm increased the precision of the maternal hemoglobin estimates without changing the β coefficients, and did not markedly influence the ARV arm results.

### Table 2

Inflammation-adjusted Hb and markers of iron status in the subsample BAN Study mother–infant dyads

<table>
<thead>
<tr>
<th>Mother</th>
<th>Initial measurement²</th>
<th>2 wk</th>
<th>6 wk</th>
<th>24 wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb, g/L</td>
<td>125 ± 16 (337)</td>
<td>122 ± 14 (159)</td>
<td>126 ± 12 (496)</td>
<td></td>
</tr>
<tr>
<td>Adverse event³ (&lt;100 g/L), %</td>
<td>6.5</td>
<td>6.9</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>Anemic (&lt;120 g/L), %</td>
<td>35.5</td>
<td>40.25</td>
<td>29.6</td>
<td></td>
</tr>
<tr>
<td>Plasma ferritin, μg/L</td>
<td>29.8 ± 37.7 (351)</td>
<td>43.5 ± 64.1 (167)</td>
<td>32.6 ± 43.7 (518)</td>
<td></td>
</tr>
<tr>
<td>Deficient (&lt;15 μg/L), %</td>
<td>40.2</td>
<td>31.7</td>
<td>33.8</td>
<td></td>
</tr>
<tr>
<td>Plasma TfR, mg/L</td>
<td>5.7 ± 2.6 (348)</td>
<td>5.7 ± 3.9 (165)</td>
<td>4.9 ± 2.2 (313)</td>
<td></td>
</tr>
<tr>
<td>Elevated (&gt;8.3 mg/L), %</td>
<td>12.9</td>
<td>16.4</td>
<td>7.2</td>
<td></td>
</tr>
<tr>
<td>Elevated inflammatory markers, %</td>
<td>42.9</td>
<td>22.2</td>
<td>16.4</td>
<td></td>
</tr>
<tr>
<td>CRP (&gt;5 mg/L)</td>
<td>77.0</td>
<td>48.7</td>
<td>33.0</td>
<td></td>
</tr>
<tr>
<td>AGP (&gt;1 g/L)</td>
<td>23.4</td>
<td>10.6</td>
<td>70.0</td>
<td></td>
</tr>
<tr>
<td>Anemic (&lt;105 g/L), %</td>
<td>461 ± 340 (351)</td>
<td>315 ± 229 (167)</td>
<td>42 ± 103 (618)</td>
<td></td>
</tr>
<tr>
<td>Plasma ferritin, μg/L</td>
<td>2.0</td>
<td>6.0</td>
<td>31.1</td>
<td></td>
</tr>
<tr>
<td>Plasma TfR, mg/L</td>
<td>3.5 ± 1.9 (348)</td>
<td>3.3 ± 1.9 (165)</td>
<td>6.7 ± 3.4 (613)</td>
<td></td>
</tr>
<tr>
<td>Elevated (&gt;8.3 mg/L), %</td>
<td>1.7</td>
<td>3.0</td>
<td>22.2</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2 Notes

1. Values are means ± SDs (n) or percentages. Values were adjusted for inflammation using group-specific correction factors estimated from ratios of medians for the various iron indicators (27). AGP, plasma α1-acid glycoprotein; BAN, Breastfeeding, Antiretroviral and Nutrition; CRP, plasma C-reactive protein; Hb, hemoglobin; TfR, soluble transferrin receptor.
2. Initial values were obtained at 2 or 6 wk due to insufficient plasma availability at 2 wk.
3. Defined as greater than or equal to the mild adverse event as described in the DAIDS toxicity tables for severe adverse events (30).
4. Defined as greater than or equal to the mild adverse event cut points given in the DAIDS toxicity tables for severe adverse events (30): 1–21 d, Hb <130 g/L; 22–35 d, Hb <110 g/L; 36–66 d, Hb <94 g/L; ≥66 d, Hb <109 g/L.
5. Cut points for Hb are not available for infants <3 mo of age.
6. Ferritin <30 μg/L at 2–6 wk and <12 μg/L at 24 wk.
In the subsample, change in inflammation-adjusted maternal TfR and hemoglobin, but not ferritin, was associated with change in infant values (Table 3). An increase in maternal TfR was associated with an increase in infant TfR from 2 or 6 to 24 wk, suggesting that worsening maternal iron status was related to worsening infant iron status. In all models, initial infant values were strong predictors of change in iron markers; higher values initially were associated with a smaller change in values from 2 or 6 to 24 wk. Maternal and infant ARV regimens were not associated with infant TfR, hemoglobin, or ferritin. Models unadjusted for inflammation depicted similar associations, but there was a strengthening of the sex association in the unadjusted hemoglobin models compared with the inflammation-adjusted model. Although associations were observed between some continuous maternal and infant markers, no associations were observed between depleted maternal iron stores at 2 or 6 wk (ferritin < 15 μg/L) and risk of depleted infant iron stores at either 2 or 6 and 24 wk (2 or 6 wk: ferritin < 30 μg/L; 12 wk: < 12 μg/L at 24 wk) (2 or 6 wk: OR = 2.06; 95% CI: 0.64, 6.59; P = 0.22; 24 wk: OR = 0.99; 95% CI: 0.65, 1.50; P = 0.95).

**Discussion**

In our study of HIV-infected Malawian mothers and their infants, maternal hemoglobin and TfR were associated with infant values during exclusive breastfeeding. Maternal iron status during pregnancy was associated with subsequent infant iron status, as described by others (7,31–33); more than half of the mothers in the longitudinal sample had mild anemia during pregnancy, which was associated with lower infant hemoglobin at birth. Few studies, however, have investigated an association between maternal iron status during lactation and infant iron status postpartum in exclusively breastfed infants, taking into account the mother’s initial influence on infant iron status.

Initial maternal iron concentrations at birth and at 2 or 6 wk indicate that despite reported provision of antenatal iron supplementation, iron stores were depleted in many women during pregnancy, predisposing them and their infants (via fetal iron acquisition during pregnancy) to poor iron status. Although many women had impaired iron status, initial infant hemoglobin and iron concentrations at birth and/or infant iron stores at 2 or 6 wk were adequate; mean infant hemoglobin was within normal levels and few infants had depleted iron stores or tissue iron depletion. Between birth and 24 wk, infant iron indicators changed dramatically. During this period, senescent fetal hemoglobin lyses, erythropoiesis slows, and vascular volume increases, leading to a decrease in hemoglobin. In addition, there is a small increase in ferritin and subsequent decline thereafter as stores are used (10). Although few infants were deficient initially, 24-wk values indicate worsening iron status, suggesting that infant stores at birth were insufficient for this period and that breast milk iron concentrations may have been inadequate to supply the iron needs of the infant.

In the longitudinal model, higher maternal hemoglobin was associated with higher infant hemoglobin at 12, 18, and 24 wk. Similarly, in the subsample, after adjustment for inflammation, an increase in inflammation-adjusted maternal hemoglobin from 2 to 6 to 24 wk was associated with an increase in infant hemoglobin. We are unaware of a study sample similar to ours with concurrent maternal and infant hemoglobin concentrations measured longitudinally. However, a previous study found that maternal hemoglobin at delivery was positively linearly associated with newborn total body iron and hemoglobin in HIV-positive and HIV-negative Zimbabwean dyads (6). Because we controlled for initial hemoglobin, our findings suggest that this association may extend postpartum. Larger increases in maternal TfR also were associated with larger increases in infant TfR during breastfeeding, suggesting that worsening maternal iron status contributed to worsening infant status. Maternal iron stores must be depleted for tissue iron depletion to manifest as increased TfR concentrations; thus, our observed association between maternal and infant TfR suggests that mothers with severely impaired iron status may have impaired breast milk iron concentrations or some other unmeasured factor, or that controlling for initial infant hemoglobin does not adequately account for their initial iron stores.

We did not observe an association between maternal and infant ferritin, which is similar to previous reports where maternal ferritin was measured in late pregnancy. Although few infants were deficient initially, a small increase in ferritin and subsequent decline thereafter as stores are used (10) may not be comparable to our study, as we have postpartum plasma infant ferritin measurements (35). We are unaware of other studies reporting associations between postpartum maternal and infant ferritin. Given the underlying mechanisms to protect and maximize iron transfer to the fetus even with the

![FIGURE 2](https://academic.oup.com/jn/article-abstract/144/3/367/4571704)
Inflammation-adjusted

<table>
<thead>
<tr>
<th></th>
<th>Log plasma TFR (n = 513)</th>
<th>Hb (g/L; n = 496)</th>
<th>Log plasma ferritin (n = 518)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)</td>
<td>P</td>
<td>β (95% CI)</td>
</tr>
<tr>
<td>Change in maternal value</td>
<td>0.18 (0.06, 0.29)</td>
<td>&lt;0.001</td>
<td>0.13 (0.03, 0.23)</td>
</tr>
<tr>
<td></td>
<td>-0.66 (-0.72, -0.60)</td>
<td>&lt;0.001</td>
<td>-0.89 (-0.94, -0.83)</td>
</tr>
<tr>
<td>Maternal initial value</td>
<td>0.23 (0.14, 0.33)</td>
<td>&lt;0.001</td>
<td>0.10 (0.02, 0.18)</td>
</tr>
<tr>
<td>Infant birth weight</td>
<td>-0.23 (-0.32, -0.14)</td>
<td>&lt;0.001</td>
<td>4.58 (2.17, 7.00)</td>
</tr>
<tr>
<td>Maternal ARV intervention</td>
<td>-0.01 (-0.10, -0.09)</td>
<td>0.85</td>
<td>1.01 (-1.41, 3.43)</td>
</tr>
<tr>
<td>Infant ARV intervention</td>
<td>0.03 (-0.05, 0.12)</td>
<td>0.43</td>
<td>-1.14 (-3.47, 1.19)</td>
</tr>
<tr>
<td>Initial measure at 6 wk</td>
<td>0.21 (0.13, 0.28)</td>
<td>&lt;0.001</td>
<td>3.19 (0.49, 5.89)</td>
</tr>
<tr>
<td>Female gender</td>
<td>-0.19 (-0.26, -0.12)</td>
<td>&lt;0.001</td>
<td>1.52 (-0.36, 3.41)</td>
</tr>
</tbody>
</table>

Inflammation-unadjusted

<table>
<thead>
<tr>
<th></th>
<th>Log plasma TFR (n = 513)</th>
<th>Hb (g/L; n = 496)</th>
<th>Log plasma ferritin (n = 518)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)</td>
<td>P</td>
<td>β (95% CI)</td>
</tr>
<tr>
<td>Change in maternal value</td>
<td>0.17 (0.06, 0.29)</td>
<td>0.004</td>
<td>0.15 (0.04, 0.25)</td>
</tr>
<tr>
<td></td>
<td>-0.65 (-0.71, -0.58)</td>
<td>&lt;0.001</td>
<td>-0.88 (-0.94, -0.83)</td>
</tr>
<tr>
<td>Maternal initial value</td>
<td>0.24 (0.14, 0.33)</td>
<td>&lt;0.001</td>
<td>0.09 (0.01, 0.17)</td>
</tr>
<tr>
<td>Infant birth weight</td>
<td>-0.23 (-0.33, -0.14)</td>
<td>&lt;0.001</td>
<td>4.33 (1.93, 6.74)</td>
</tr>
<tr>
<td>Maternal ARV intervention</td>
<td>-0.01 (-0.11, -0.08)</td>
<td>0.81</td>
<td>1.28 (-1.14, 3.69)</td>
</tr>
<tr>
<td>Infant ARV intervention</td>
<td>0.04 (-0.05, 0.13)</td>
<td>0.41</td>
<td>-1.15 (-3.47, 1.17)</td>
</tr>
<tr>
<td>Initial measure at 6 wk</td>
<td>0.20 (0.11, 0.27)</td>
<td>&lt;0.001</td>
<td>3.50 (0.84, 6.17)</td>
</tr>
<tr>
<td>Female gender</td>
<td>-0.20 (-0.27, -0.12)</td>
<td>&lt;0.001</td>
<td>4.12 (2.24, 6.00)</td>
</tr>
</tbody>
</table>

1 The LNS arm was not included in the model to isolate the effects of maternal iron status independent of the study supplement. The maternal ARV and infant ARV intervention groups were compared with the groups that received no ARV intervention. Mother and infant values were adjusted for inflammation using group-specific correction factors estimated from ratios of medians for the various iron indicators (28). ARV, antiretroviral drug; BAN, Breastfeeding, Antiretroviral and Nutrition; Hb, hemoglobin; LNS, lipid-based nutrient supplement; TFR, soluble transferrin receptor.

TABLE 3  Linear regression models of the association between change in maternal iron status and change in infant iron status from 2 or 6 wk to 24 wk in the subsample of BAN Study mother–infant dyads

The presence of maternal anemia (evident from high infant ferritin concentrations at 2 or 6 wk) (11), coupled with the many factors that influence infant iron endowment at birth, including gestational age (7) and timing of cord clamping (36), as well as senescent fetal hemoglobin lysis (10), the lack of an association between maternal and infant ferritin is not surprising. This is further supported by the absence of an association between the maternal ferritin measurement at 2 or 6 wk postpartum and change in infant ferritin from initial measure to 24 wk in the regression model.

This research has some limitations. We do not know whether all mothers received and took iron supplements during pregnancy, but by controlling for the mother’s initial measurement this may not have biased our findings. Maternal and infant hemoglobin measurements at birth were conducted on average about 1 d postpartum. Because delivery is an inflammatory process (37), it is possible that infant hemoglobin concentrations were lowered at this time; but an association between inflammation at delivery and infant hemoglobin concentrations has not been reported. Infant hemoglobin values at birth are included in the longitudinal model; therefore, the inflammatory processes at delivery possibly could have attenuated the association between birth hemoglobin and later concentrations. Furthermore, we do not know if the observed maternal and infant hemoglobin associations are due to some other unmeasured factor or are residual effects from pregnancy. Because of insufficient plasma availability at 2 wk, we have initial iron indicators at 2 times in the subsample. During this period, infant iron status, particularly hemoglobin, changes dramatically; thus, we accounted for timing of measurement using a dummy variable. Selection bias may have influenced our findings. In the longitudinal sample, we excluded about 19% of randomly assigned dyads who lacked the measurements required for inclusion in the analysis. Compared with the randomly assigned dyads in the longitudinal sample, worse-off infants and mothers were lost to follow-up or excluded. Similarly, subsample dyads were healthier than randomly assigned infants. Therefore, we may have underestimated the observed relations between maternal and infant iron markers. Furthermore, the longitudinal sample size was smaller at 24 wk due to attrition and weaning, therefore 24 wk effects may have been attenuated. Finally, we also do not know whether the method we used to correct iron indicators for inflammation (27) is valid from 2 to 24 wk; however, the corrections did not have much influence on the interpretation of the data, which may indicate that this correction may not be indicated in this period.

This study also has many strengths. Importantly, detailed exclusive breastfeeding reports allowed for the exclusion of infants who potentially received other sources of iron in complementary foods, strengthening our findings. This is the first study to characterize the relation between maternal and infant iron status using multiple iron indicators during exclusive breastfeeding. Understanding these relations is especially important in the context of HIV to guide future interventions and programs to promote maternal and infant health. We focused on the early postpartum period, a period where infant iron status is not well characterized, which improved our understanding of hematologic dynamics during this time.

Because we controlled for the infant’s iron status at birth, these results might be explained by an effect of breast milk iron because breast milk was the sole source of nutrition for infants at this time. Previous studies evaluating the association between maternal iron status during lactation and breast milk iron content have been inconsistent (38–42). Several studies have shown that maternal hemoglobin and serum iron concentrations are related to breast milk iron concentrations, especially in anemic women or women with impaired iron status markers (41–43); however, whether breast milk iron concentrations subsequently...
are associated with infant iron status is still equivocal (43). Further research to understand how iron status markers relate to breast milk iron concentrations is needed, particularly in light of the high prevalence of infant anemia at 6 mo in this population.

Although poor maternal iron status and exclusive breastfeeding are likely to occur in other populations, we do not know if our findings are generalizable to other settings in HIV-infected and uninfected populations with varying concentrations of maternal iron deficiency or anemia. Because of study inclusion criteria, BAN Study mothers were healthier than other women in Malawi and low birth weight infants (<2 kg) were excluded. Furthermore, dyads were provided high-quality health care for the duration of the study. As such, the association between changes in maternal and infant iron status among dyads with very poor maternal iron status and low infant birth weight is unknown. However, given the observed association between maternal and infant hemoglobin and TfR, and the strong sustained effects of initial infant iron markers on later status, optimizing maternal iron status in pregnancy and postpartum is important for reducing risk of iron depletion in infants.

Acknowledgments

We thank the UNC project team in Lilongwe, including: Yusuf Ahmed, Mounir Ait-Khaled, Sandra Albrecht, Shrikant Bangdiwala, Ronald Bayer, Brian Bramson, Emily Bobrow, Nicola Boyle, Sal Butera, Charity Chavula, Joseph Chimerang’ambwe, Maggie Chigwenembe, Maria Chikasema, Norah Chikhungu, David Chilongozii, Grace Chiuzu, Lenesi Chome, Anne Cole, Amanda Corbett, Amy Corneli, Anna Dow, Ann Duerr, Henrri Eliya, Sascha Ellington, Joseph Eron, Sherry Farr, Yvonne Owens Ferguson, Susan Fiscus, Valerie Flax, Ali Fokar, Shannon Galvin, Laura Guay, Chad Heilig, Irving Hoffman, Elizabeth Hooten, Mina Hosseinipour, Michael Hudgens, Stacy Hurst, Lisa Hyde, George Joaki (deceased), David Jones, Elizabeth Jordan-Bell, Esmie Kamanga, Gift Kamanga, Coxcilly Kampani, Portia Kamthunzi, Deborah Kamwendo, Cecilia Kanyama, Angela Kashuba, Damson Kathryn, Peter Kazembe, Caroline C. King, Rodney Knight, Robert Krysiak, Jacob Kumbwenda, Hana Lee, Eddie Loeliger, Dustin Long, Misheck Luhanga, Victor Madhlopa, Maganizo Majawa, Alice Maida, Cheryl Marcus, Francis Martinson, Navdeep Thooper, Chrissie Matiki (deceased), Douglas Mayers, Isabel Mayuni, Marita McDonough, Joyce Meme, Ceppie Merry, Khama Mita, Chimwemwe Mkomawanthu, Gertrude Mndala, Ibrahim Mtimuni, Jane Muita, Noel Mumba, Bonface Musis, Mndala, Agnes Moses, Albans Msika, Wezi Msungama, Beatrice Mitmuni, Jane Muza, Noel Mumba, Bonface Musis, Christopher Sellers, Diane Shugars, Dorothy Sichali, Wendy Snowden, Alice Soko, Allison Spensley, Jean-Marc Steens, Christopher Sellers, Diane Shugars, Dorothy Sichali, Wendy Snowden, Alice Soko, Allison Spensley, Jean-Marc Steens, Martin Tembo, Roshan Thomas, Hsiao-Chuan Tien, Beth Tohill, Esther Waalberg, Jeffery Wiener, Cathy Wilfert, Patricia Wiyo, Innocent Zgambo, and Chifundo Zimba. We also thank Anna Maria Siega-Riz, Michael Hudgens, Catherine Zimmer, Valerie Flax, and Lindsay Jaacks for their input on the manuscript.

M.E.B., C.S.C., A.P.K., D.J.J., C.M.v.d.H., and L.S.A. contributed to the trial design; D.K., C.S.C., Z.K.K., and G.T. contributed to the data collection; L.H.A. supervised and S.S.-F. conducted biomarker assays for the subsample; E.M.W., E.J.D., and L.S.A. contributed to interpretation of data analysis; E.M.W. performed the data analysis, wrote the manuscript, and had primary responsibility for the final content; and M.E.B., L.S.A., L.H.A., and E.M.W. contributed to manuscript revisions. All authors read and approved the final version of the paper as well as contributed to data interpretation and the intellectual content of the study.

Literature Cited


16. Flax YL, Bentley ME, Chasela CS, Kayira D, Hudgens MG, Knight RJ, Soko A, Jamieson DJ, van der Horst CM, Adair LS. Use of lipid-based...


